Highlights

  • EchoSolv AS has been deployed at Mount Sinai Health System in New York, a seven-hospital network ranked No. 1 in New York and No. 2 nationally for Cardiology, Heart &Amp; Vascular Surgery by U.S. News &Amp; World Report.
  • The deployment marks the first large-scale integration of EchoSolv AS into a top-tier US academic medical centre, supporting the company's strategy of targeting prominent cardiovascular institutions.
  • EIQ shares fell 13.97% to A$0.985 on 28 April 2026 with 6.4 million shares traded, while the company's Market Capitalisation stood at approximately A$756.68 million.

Echo IQ Limited (ASX:EIQ) experienced a sharp share price decline on 28 April 2026, falling A$0.160 or 13.97% to close at A$0.985. The session saw 6,426,754 shares traded with a bid-offer range of A$0.980 to A$0.990, indicating active selling pressure on the day of what was ostensibly a highly positive commercial announcement. The company's Market Capitalisation at that price was approximately A$756.68 million.

The paradox of a significant share price decline on a milestone news day is a familiar dynamic in the small-to-mid-cap technology and MedTech sector on the ASX. When a company's share price has run up in anticipation of a major announcement, the actual release of that news can trigger profit-taking. Investors should assess the fundamental significance of the Mount Sinai deployment separately from its immediate share price impact. The underlying question — whether this agreement represents the beginning of a scalable US commercial rollout — is arguably more important for the medium-term Investment case than the day's trading action.

The Mount Sinai Deployment: Strategic Significance

The deployment of EchoSolv AS at Mount Sinai Health System represents what is arguably Echo IQ's most significant commercial milestone to date. Mount Sinai is not merely a large hospital — it is a globally recognised academic medical centre with a footprint that includes seven hospitals, more than 400 outpatient practices, and approximately 3,760 beds across its New York campuses. Its affiliated medical school, the Icahn School of Medicine at Mount Sinai, is one of the most research-active institutions in US medicine.

More specifically, Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital holds the No. 1 ranking in New York and No. 2 nationally for Cardiology, Heart &Amp; Vascular Surgery in U.S. News &Amp; World Report's 2025-26 Best Hospitals rankings. This is not a peripheral institution seeking to experiment with novel technology — it is the very definition of clinical Leadership in cardiovascular medicine. Deployment at an institution of this calibre provides Echo IQ with a high-credibility reference site that will carry significant weight in conversations with other prospective US hospital customers.

EchoSolv AS: The Technology and Its Clinical Role

EchoSolv AS is an AI-based decision support software indicated for use as an adjunct to echocardiography in the assessment of severe aortic stenosis. Aortic stenosis — a narrowing of the aortic valve opening that restricts blood flow from the heart — is one of the most common and serious valvular heart diseases, particularly in elderly populations. Its accurate diagnosis is clinically critical because severe aortic stenosis that goes undetected or is underdiagnosed can deprive patients of access to highly effective interventional treatments, including transcatheter aortic valve replacement procedures.

EchoSolv AS is designed to provide a measurement-based second look that highlights cases where severe aortic stenosis may have been missed or under-graded in routine echocardiography workflows. As articulated by Dr. Stamatios Lerakis, Director of the Cardiovascular Imaging Program for Mount Sinai Health System, the product can identify patients with aortic stenosis who might otherwise go undiagnosed and miss out on therapeutic advances in aortic valve disease management. Dr. Lerakis characterised EchoSolv AS as an adjunct that strengthens patient care while preserving the echocardiographer's interpretive authority.

Commercial Strategy and US Market Expansion

Echo IQ's US strategy has been explicitly oriented toward deployment in leading hospital systems, and the Mount Sinai agreement is a direct execution of that stated approach. Nick Lubbers, the company's US President and General Manager, described the deployment as representing 'more than a single large-scale deployment,' pointing to its role in reflecting the company's broader growth trajectory as it builds partnerships with prominent cardiovascular institutions.

The company's ability to secure agreements with high-profile institutions like Mount Sinai is both commercially valuable and strategically important. In the healthcare AI software market, particularly in the US, institutional adoption by prestigious academic medical centres creates a de facto endorsement that can accelerate penetration with smaller hospital systems and community cardiology practices. The Mount Sinai deployment provides Echo IQ with a reference case it can Leverage in its ongoing commercial discussions with other prospective US healthcare providers.

Research and Product Development Opportunities

Beyond its direct commercial value, the Mount Sinai engagement opens potential research collaboration opportunities for Echo IQ. Academic medical centres of Mount Sinai's stature are typically research-active institutions with the patient volumes, clinical expertise, and publication networks to generate peer-reviewed evidence supporting the clinical Utility of novel diagnostic tools. For Echo IQ, which is also pursuing new product development, access to a high-Volume, high-complexity cardiovascular program at an institution like Mount Sinai could provide real-world performance data and research outputs that support future regulatory filings, expanded indications, and clinical guideline integration.

The company has been transparent in noting that the Mount Sinai deployment is viewed as providing both commercial traction and future research opportunities. This dual-use framing of the relationship is consistent with how leading MedTech companies position academic centre partnerships — as foundational relationships that generate both near-term Revenue and longer-term evidence that underpins market expansion.

Forward Outlook

Echo IQ exits the April 2026 period with its most significant US commercial reference site secured and a clearly articulated strategy of continuing to target prominent cardiovascular institutions. The company has confirmed it is continuing to engage with prospective US healthcare providers regarding further EchoSolv AS opportunities, and will provide updates as appropriate. For investors, the key metrics to monitor in coming quarters will be the number of additional US deployments secured, evidence of active clinical utilisation at Mount Sinai, and any updates on new product development initiatives that could broaden the company's addressable market beyond the current aortic stenosis indication.